METTL3-mediated m6A modification stabilizes YOD1 to promote Bcl-xL-dependent enzalutamide resistance in prostate cancer
Year: 2026
Type: article
Abstract: Resistance to enzalutamide remains a major challenge in advanced prostate cancer, but the mechanisms linking epitranscriptomic regulation to apoptotic escape remain incompletely understood. By integrating MeRIP-seq and RNA-seq analyses of parental and enzalutamide-resistant prostate cancer cells, we identified the deubiquitinase YOD1 as a candidate mediator of resistance. YOD1 depletion enhanced enzalutamide-induced apoptosis and suppressed resistant tumor growth in vitro and in vivo. Mechanistically, METTL3-dependent m6A modification at A1360 promoted the association of YOD1 mRNA with IGF2BP2, thereby enhancing transcript stability and YOD1 expression. YOD1 associated with Bcl-xL and limited its K48-linked ubiquitination and proteasomal degradation. Catalytic-mutant and genetic rescue experiments supported the requirement for YOD1 deubiquitinase activity and positioned Bcl-xL as a functional downstream effector. Pharmacological inhibition of Bcl-xL with A-1,155,463 enhanced the response to enzalutamide in cellular and resistant xenograft models. In addition, immunohistochemical analysis of prostate cancer specimens revealed positive associations among METTL3, YOD1 and Bcl-xL protein abundance. Together, these findings support an m6A-deubiquitinase-Bcl-xL regulatory cascade that contributes to apoptotic resistance during enzalutamide treatment. This pathway may represent a potential therapeutic vulnerability, although its clinical relevance requires further validation.
Language: English
Topic: RNA modifications and cancer
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $4,290
Award: G1434939514
OpenAlex ID: W7233584700
